$ENTA
ENANTA PHARMACEUTICALS INC

2021 Q1 Form 10-Q Financial Statement

#000156459021026025 Filed on May 10, 2021

View on sec.gov

Income Statement

Concept 2021 Q1 2020 Q1
Revenue $20.13M $27.62M
YoY Change -27.11% -30.31%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $8.330M $6.880M
YoY Change 21.08% 1.47%
% of Gross Profit
Research & Development $41.51M $32.61M
YoY Change 27.28% -4.54%
% of Gross Profit
Depreciation & Amortization $840.0K $920.0K
YoY Change -8.7% 15.0%
% of Gross Profit
Operating Expenses $41.51M $32.61M
YoY Change 27.28% -20.35%
Operating Profit -$29.70M -$11.88M
YoY Change 150.11% 810.66%
Interest Expense $550.0K $1.950M
YoY Change -71.79% -13.14%
% of Operating Profit
Other Income/Expense, Net $545.0K $1.950M
YoY Change -72.05% -13.14%
Pretax Income -$29.16M -$9.925M
YoY Change 193.75% -1154.73%
Income Tax $7.110M -$3.920M
% Of Pretax Income
Net Earnings -$22.05M -$6.005M
YoY Change 267.11% -244.87%
Net Earnings / Revenue -109.5% -21.74%
Basic Earnings Per Share -$1.09 -$0.30
Diluted Earnings Per Share -$1.09 -$0.30
COMMON SHARES
Basic Shares Outstanding 20.17M 19.92M
Diluted Shares Outstanding 20.17M 19.92M

Balance Sheet

Concept 2021 Q1 2020 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $375.9M $355.3M
YoY Change 5.8% -4.02%
Cash & Equivalents $77.73M $74.30M
Short-Term Investments $298.8M $280.9M
Other Short-Term Assets $32.10M $19.80M
YoY Change 62.12% 40.43%
Inventory
Prepaid Expenses
Receivables $20.10M $27.60M
Other Receivables $0.00 $0.00
Total Short-Term Assets $428.2M $402.7M
YoY Change 6.33% -4.98%
LONG-TERM ASSETS
Property, Plant & Equipment $14.00M $17.60M
YoY Change -20.45% 53.04%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $24.50M $80.10M
YoY Change -69.41% 385.45%
Other Assets $1.000M $13.10M
YoY Change -92.37% 33.67%
Total Long-Term Assets $39.60M $110.8M
YoY Change -64.26% 193.12%
TOTAL ASSETS
Total Short-Term Assets $428.2M $402.7M
Total Long-Term Assets $39.60M $110.8M
Total Assets $467.8M $513.5M
YoY Change -8.9% 11.24%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $5.700M $5.900M
YoY Change -3.39% -33.71%
Accrued Expenses $15.74M $9.807M
YoY Change 60.54% -15.46%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $26.60M $19.50M
YoY Change 36.41% -4.88%
LONG-TERM LIABILITIES
Long-Term Debt $1.500M $1.600M
YoY Change -6.25% -15.79%
Other Long-Term Liabilities $994.0K $1.036M
YoY Change -4.05% -68.11%
Total Long-Term Liabilities $994.0K $1.036M
YoY Change -4.05% -68.11%
TOTAL LIABILITIES
Total Short-Term Liabilities $26.60M $19.50M
Total Long-Term Liabilities $994.0K $1.036M
Total Liabilities $31.70M $27.50M
YoY Change 15.27% 8.4%
SHAREHOLDERS EQUITY
Retained Earnings
YoY Change
Common Stock $314.2M
YoY Change 8.83%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $436.0M $486.0M
YoY Change
Total Liabilities & Shareholders Equity $467.8M $513.5M
YoY Change -8.9% 11.25%

Cashflow Statement

Concept 2021 Q1 2020 Q1
OPERATING ACTIVITIES
Net Income -$22.05M -$6.005M
YoY Change 267.11% -244.87%
Depreciation, Depletion And Amortization $840.0K $920.0K
YoY Change -8.7% 15.0%
Cash From Operating Activities -$4.580M $14.68M
YoY Change -131.2% -51.21%
INVESTING ACTIVITIES
Capital Expenditures -$130.0K -$350.0K
YoY Change -62.86% -86.06%
Acquisitions
YoY Change
Other Investing Activities $25.59M $28.10M
YoY Change -8.93% 633.68%
Cash From Investing Activities $25.46M $27.75M
YoY Change -8.25% 2002.27%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 1.150M 4.350M
YoY Change -73.56% 1573.08%
NET CHANGE
Cash From Operating Activities -4.580M 14.68M
Cash From Investing Activities 25.46M 27.75M
Cash From Financing Activities 1.150M 4.350M
Net Change In Cash 22.03M 46.78M
YoY Change -52.91% 47.71%
FREE CASH FLOW
Cash From Operating Activities -$4.580M $14.68M
Capital Expenditures -$130.0K -$350.0K
Free Cash Flow -$4.450M $15.03M
YoY Change -129.61% -53.9%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2019 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y6M
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y9M18D
CY2020Q1 us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
us-gaap:RoyaltyMember
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P6Y9M18D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P5Y4M24D
us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
us-gaap:RoyaltyMember
us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
us-gaap:RoyaltyMember
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
51875000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
65388000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
15703000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
13805000
us-gaap Costs And Expenses
CostsAndExpenses
93874000
us-gaap Costs And Expenses
CostsAndExpenses
79193000
us-gaap Operating Income Loss
OperatingIncomeLoss
-41999000
us-gaap Operating Income Loss
OperatingIncomeLoss
996000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
1222000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
4026000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1222000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
4026000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-40777000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
5022000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
78171000
CY2020Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6884000
CY2020Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
32610000
CY2020Q1 us-gaap Costs And Expenses
CostsAndExpenses
39494000
CY2020Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-9925000
CY2020Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-11875000
CY2020Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
1950000
CY2020Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1950000
CY2020Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-3920000
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-6005000
CY2020Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.30
CY2020Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.30
CY2020Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
19922000
CY2020Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
19922000
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-6005000
CY2020Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
119000
CY2020Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
374000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-10404000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-2416000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
109000
us-gaap Net Income Loss
NetIncomeLoss
-30373000
us-gaap Net Income Loss
NetIncomeLoss
7438000
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.51
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.37
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.51
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.36
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
20131000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
19836000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
20131000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
20692000
us-gaap Net Income Loss
NetIncomeLoss
-30373000
us-gaap Net Income Loss
NetIncomeLoss
7438000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
0
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
147000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-789000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
462000
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-789000
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
462000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-31162000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
7900000
CY2020Q1 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
374000
CY2020Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-5631000
CY2019Q4 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
5098000
CY2019Q3 us-gaap Stockholders Equity
StockholdersEquity
462492000
CY2019Q4 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
2306000
CY2019Q4 us-gaap Restricted Stock Value Shares Issued Net Of Tax Withholdings
RestrictedStockValueSharesIssuedNetOfTaxWithholdings
-1140000
CY2019Q4 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
88000
CY2019Q4 us-gaap Net Income Loss
NetIncomeLoss
13443000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
482287000
CY2020Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
4716000
CY2020Q1 us-gaap Restricted Stock Value Shares Issued Net Of Tax Withholdings
RestrictedStockValueSharesIssuedNetOfTaxWithholdings
-358000
CY2020Q4 us-gaap Restricted Stock Value Shares Issued Net Of Tax Withholdings
RestrictedStockValueSharesIssuedNetOfTaxWithholdings
-534000
CY2020Q4 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4883000
CY2020Q4 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-439000
CY2020Q4 us-gaap Net Income Loss
NetIncomeLoss
-8328000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
451995000
CY2021Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1152000
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
5280000
CY2021Q1 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-350000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-22045000
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
436032000
us-gaap Profit Loss
ProfitLoss
-30373000
us-gaap Profit Loss
ProfitLoss
7438000
us-gaap Share Based Compensation
ShareBasedCompensation
10163000
us-gaap Share Based Compensation
ShareBasedCompensation
10076000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
1705000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
1819000
us-gaap Deferred Income Taxes And Tax Credits
DeferredIncomeTaxesAndTaxCredits
-1224000
enta Premium On Marketable Securities
PremiumOnMarketableSecurities
2398000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
379000
enta Increase Decrease In Operating Lease Right Of Use Assets
IncreaseDecreaseInOperatingLeaseRightOfUseAssets
-1311000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-731000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-5585000
enta Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-1484000
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
-964000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
27037000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
171884000
us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
163273000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
842000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-9453000
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
1498000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
7022000
CY2021Q1 us-gaap Liabilities Fair Value Disclosure
LiabilitiesFairValueDisclosure
1479000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
17000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
2517000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
1997000
us-gaap Year Founded
YearFounded
1995
us-gaap Use Of Estimates
UseOfEstimates
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Use of Estimates</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amounts of revenues and expenses during the reporting period. Significant estimates and assumptions reflected in these consolidated financial statements include, but are not limited to, <span style="Background-color:#FFFFFF;">management’s judgments with respect to its revenue arrangements; valuation of Series 1 nonconvertible preferred stock and stock-based awards; the accrual of research and development expenses, and the accounting for income taxes, including uncertain tax positions and the valuation of net deferred tax assets. </span>Estimates are periodically reviewed in light of changes in circumstances and other facts. The future developments of the COVID-19 pandemic which may directly or indirectly impact the Company’s business include <span style="color:#000000;">quarantines, border closures, increased border controls, travel restrictions, shelter-in-place orders and shutdowns, business closures, cancellations of public gatherings and other measures. </span>The Company has made estimates of the impact of COVID-19 in the Company’s consolidated financial statements as of <span style="color:#000000;">March 31, 2021</span>. Actual results could differ from the Company’s estimates. </p>
CY2021Q1 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
399451000
CY2020Q3 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
413654000
CY2020Q3 us-gaap Liabilities Fair Value Disclosure
LiabilitiesFairValueDisclosure
1479000
enta Fair Value Measurements Inter Transfers Between Levels
FairValueMeasurementsInterTransfersBetweenLevels
0
enta Fair Value Measurements Inter Transfers Between Levels
FairValueMeasurementsInterTransfersBetweenLevels
0
enta Fair Value Measurements Inter Transfers Between Levels
FairValueMeasurementsInterTransfersBetweenLevels
0
CY2020Q3 enta Accrued Research And Development Expenses Current
AccruedResearchAndDevelopmentExpensesCurrent
5407000
CY2021Q1 enta Accrued Liabilities Manufacturing
AccruedLiabilitiesManufacturing
4404000
CY2020Q3 enta Accrued Liabilities Manufacturing
AccruedLiabilitiesManufacturing
2885000
CY2021Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2592000
CY2020Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
4777000
CY2021Q1 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
684000
CY2021Q1 enta Accrued Research And Development Expenses Current
AccruedResearchAndDevelopmentExpensesCurrent
7031000
CY2020Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
478000
CY2021Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1033000
CY2020Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
612000
CY2021Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
15744000
CY2020Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
14159000
CY2021Q1 us-gaap Liability For Uncertain Tax Positions Noncurrent
LiabilityForUncertainTaxPositionsNoncurrent
686000
CY2020Q3 us-gaap Liability For Uncertain Tax Positions Noncurrent
LiabilityForUncertainTaxPositionsNoncurrent
788000
CY2021Q1 us-gaap Asset Retirement Obligations Noncurrent
AssetRetirementObligationsNoncurrent
308000
CY2020Q3 us-gaap Asset Retirement Obligations Noncurrent
AssetRetirementObligationsNoncurrent
290000
CY2021Q1 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
994000
CY2021Q1 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
322874000
CY2021Q1 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
481000
CY2021Q1 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
41000
CY2021Q1 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
323314000
CY2020Q3 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
330923000
CY2020Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
1243000
CY2020Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
14000
CY2020Q3 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
332152000
CY2021Q1 us-gaap Available For Sale Securities Debt Securities Noncurrent
AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
24493000
CY2020Q3 us-gaap Available For Sale Securities Debt Securities Noncurrent
AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
32634000
CY2020Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
1078000
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
3262000
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
49.82
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
21860000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
805000
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
44.76
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
76000
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
26.27
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
105000
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
66.81
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
3886000
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
48.77
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
29478000
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
3886000
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
48.77
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
29478000
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
2312000
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
44.40
CY2021Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
25801000
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1
ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
P4Y
CY2021Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
5280000
CY2020Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4977000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
10163000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
10076000
CY2020Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4977000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
10163000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
10076000
CY2021Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
54137000
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y6M
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-22045000
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-6005000
us-gaap Net Income Loss
NetIncomeLoss
-30373000
us-gaap Net Income Loss
NetIncomeLoss
7438000
CY2021Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
20171000
CY2020Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
19922000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
20131000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
19836000
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.37
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-22045000
CY2021Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.09
CY2020Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.30
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.51
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-6005000
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.51
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.36
CY2021Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4268000
CY2020Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3714000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4307000
us-gaap Risks And Uncertainties In Entitys Business
RisksAndUncertaintiesInEntitysBusiness
The CARES Act lifts certain deduction limitations originally imposed by the Tax Cuts and Jobs Act of 2017 (the “2017 Tax Act”). Under the CARES Act, the Company is permitted to carry back net operating losses originating beginning in fiscal 2018 through fiscal 2021 for up to five years. Net operating loss carrybacks were previously prohibited under the 2017 Tax Act. The CARES Act also eliminates the 80% of taxable income limitations by allowing corporate entities to fully utilize net operating losses to offset taxable income in those prior years. In addition, the CARES Act makes qualified improvement property eligible for 15-year cost-recovery and 100% bonus depreciation.
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
2457000
CY2021Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-7110000
CY2020Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-3920000
CY2021Q1 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
686000
CY2020Q3 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
788000
us-gaap Net Income Loss
NetIncomeLoss
-30373000
us-gaap Net Income Loss
NetIncomeLoss
7438000
CY2021Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
20171000
CY2020Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
19922000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
20131000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
19836000
us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
856000
CY2021Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
20171000
CY2020Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
19922000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
20131000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
20692000
CY2021Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.09
CY2020Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.30

Files In Submission

Name View Source Status
0001564590-21-026025-index-headers.html Edgar Link pending
0001564590-21-026025-index.html Edgar Link pending
0001564590-21-026025.txt Edgar Link pending
0001564590-21-026025-xbrl.zip Edgar Link pending
enta-10q_20210331.htm Edgar Link pending
enta-10q_20210331_htm.xml Edgar Link completed
enta-20210331.xsd Edgar Link pending
enta-20210331_cal.xml Edgar Link unprocessable
enta-20210331_def.xml Edgar Link unprocessable
enta-20210331_lab.xml Edgar Link unprocessable
enta-20210331_pre.xml Edgar Link unprocessable
enta-ex311_7.htm Edgar Link pending
enta-ex312_8.htm Edgar Link pending
enta-ex321_6.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
g05my3l5gj1l000001.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending